ago1/eif2c1 antibody  (Bio-Techne corporation)

Journal: EMBO reports

Article Title: Transcript-specific induction of stop codon readthrough using a CRISPR-dCas13 system.

doi: 10.1038/s44319-024-00115-8

Figure Lengend Snippet: Figure 3. AGO1-3′UTR-targeting dCas13 enhances global translation.

Article Snippet: Anti-Ago1 antibody (Novus Biologicals, NB100-2817), Anti-GFP antibody (BioLegend, © The Author(s) EMBO reports Volume 25 | April 2024 | 2118 – 2143 2131 D ow nloaded from https://w w w .em bopress.org on A pril 24, 2024 from IP 113.173.236.9.

Techniques:

Journal: EMBO Reports

Article Title: Transcript-specific induction of stop codon readthrough using a CRISPR-dCas13 system

doi: 10.1038/s44319-024-00115-8

Figure Lengend Snippet: Reagents and tools table

Article Snippet: Anti-Ago1 , Novus Biologicals , NB100-2817.

Techniques: Recombinant, Modification, Expressing, Sequencing, Reporter Assay, Cell Culture, Membrane, Western Blot, Protease Inhibitor, Real-time Polymerase Chain Reaction, Imaging

Journal: EMBO Reports

Article Title: Transcript-specific induction of stop codon readthrough using a CRISPR-dCas13 system

doi: 10.1038/s44319-024-00115-8

Figure Lengend Snippet: Reagents and tools table

Article Snippet: Anti-Ago1 , Novus Biologicals , NB100-2817.

Techniques: Recombinant, Modification, Expressing, Sequencing, Reporter Assay, Cell Culture, Membrane, Western Blot, Protease Inhibitor, Real-time Polymerase Chain Reaction, Imaging

Journal: Biochimica et biophysica acta

Article Title: Polycomb YY1 is a critical interface between epigenetic code and miRNA machinery after exposure to hypoxia in malignancy.

doi: 10.1016/j.bbamcr.2015.01.009

Figure Lengend Snippet: Fig. 6. Recruitment of YY1 polycomb and RNAi machinery components. A) Bar graph of qRT-PCR for primiRNA 16, following RNA ChIP assay using YY1 antibody with or without DNase treatment in U2os pBlock-it cells. *p b 0.01 vs. input and IP:IgG; **p b 0.01 vs. input and IP:IgG. B) Bar graph of qRT-PCR for primiRNA 16, after RNA ChIP assay using YY1 or IgG and then Dicer antibodies, with or without DNase treatment in U2os pBlock-it cells. ** p b 0.001 vs. input and IP:IgG. C) qRT-PCR for primiRNA 16, after RNA ChIP assay using YY1 or IgG and then Ago1 antibodies, with or without DNase treatment in U2os pBlock-it cells. D) qRT-PCR for primiRNA 200b/c after RNA ChIP assay with or without DNase treatment using YY1 antibody in U2os pBlock-it cells. * and **p b 0.001 vs. input and IP:IgG. E) Bar graph of qRT-PCR for primiRNA 200b/c after RNA ChIP assay with or without DNase treatment using YY1 or IgG and then Dicer antibodies in U2os pBlock-it cells.*and **p b 0.001 vs. input and IP:IgG. F) qRT-PCR for primiRNA 200b/c with or without DNasi treatment using YY1or IgG and then Ago1 antibodies in U2os pBlock-it cells. *and **p b 0.001 vs. input and IP:IgG. All data are calculated with 2−ΔΔCT method and reported as fold enrichment over non immunorecipitated RNA (input) amplified with specific set primers and represent mean values of three different experiments performed in triplicate ± S.D. RNA was also immunoprecipitated with IgG antibody and amplified with specific set primers as experimental control. G) Representative western blot analysis after immunoprecipitation of protein extracts from U2os pBlock-it cells. YY1 antibody immunopre- cipitation and western blot with Dicer antibody and vice versa. Immunoprecipitation with YY1 antibody and detection with Ago1 antibody and vice versa. IgG immunoprecipitation was used as experimental control.

Article Snippet: The following primary antibodies were used: Dicer (13D6) (ab14601, Abcam), Argonaute 1 (Ago1) (NB100-2817, Novus Biologicals), HIF-1α (AF1935, R&D Systems), VEGFA (AF-293-NA R&D) and VEGFA (F-5, Santa Cruz Biotechnology) and YY1 (C20, Santa Cruz Biotechnology).

Techniques: Quantitative RT-PCR, Immunoprecipitation, Control, Western Blot